Is­rael Can­cer Re­search

The Jewish Voice - - PARSHA -

Doxil, Gleevec and Vel­cade.”

"Through ex­panded fund­ing,” said Ken Ga­bel, ICRF New York Di­rec­tor of De­vel­op­ment, “we can con­tinue to sup­port the vi­tal re­search that is needed to treat and ul­ti­mately cure can­cer, while play­ing a crit­i­cal role in help­ing to keep Is­rael's finest sci­en­tific tal­ent in Is­rael. The gen­er­ous sup­port of the Deal com­mu­nity helps ICRF-funded sci­en­tists to find more cures and treat­ments for can­cer, for the ben­e­fit of all hu­man kind.”

For more in­for­ma­tion about ICRF or the July 23 event, please con­tact Ken Ga­bel, Tel. (212) 969 -9800 ext. 225, Ken. Ga­bel@icrfny.org

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.